Tumor Imaging
Oncology
PreclinicalActive
Key Facts
About TissueVision
TissueVision is a private, revenue-generating contract research organization (CRO) focused on high-resolution 3D whole-tissue imaging and analysis. The company's core technology is its TissueCyte® imaging platform, which automates tissue sectioning and multi-spectral imaging to generate terabytes of quantitative data per study, enabling large-scale projects in neuroscience, oncology, and fibrosis. With a strong foundation from MIT and NIH grant support, TissueVision serves as a critical partner for clients needing scalable, statistically powerful histological data to advance therapeutic programs from discovery through preclinical development.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |